98% of healthcare executives believe automated healthcare will improve gaps in care

In a report released by World Business Research (WBR) and Conversa Health, 98 percent of healthcare executives believed automated healthcare will be important to closing gaps in transactional care, continuous and collaborative care experiences.

The report, titled “Healthcare 2020: How Automated Patient Experiences Will Transform the Landscape,” included responses collected from interviews and surveys of134 healthcare executives. The report aimed to provide insight into how executives view automated healthcare technology, how their organization would utilize these tools and future plans of adoption.

Key findings included:

  • 87 percent of respondents believed automated healthcare would be beneficial to increasing patient engagement in their own care.
  • 82 percent of respondents see value in using automated healthcare solutions to gather patient-generated health data (PGHD).
  • 79 percent of respondents plan on integrating automated healthcare solutions within the next 24 months.
  • 49 percent of respondents are either integrating or already have integrated PGHD into their patient experience initiatives.
  • 74 percent of respondent are interested in the use of automated healthcare / AI solutions for improving continuous care experiences for their patients.
  • 98 percent of respondents think automated healthcare will help close gaps in current standards of care.

“We have been using automated technology and it has exceeded my expectations,” said Margaret Sabin, the CEO of Penrose- St. Francis Health Services, of Centura Health. “It has enabled us to engage with our patients in a way that’s convenient for them, and gives us the kind of information we need to help them manage their lives.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it. 

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%. 

HHS has thought through the ways AI can and should become an integral part of healthcare, human services and public health. Last Friday—possibly just days ahead of seating a new secretary—the agency released a detailed plan for getting there from here.